Mr. Mike Druhan reports

MEDX HEALTH AND HEALTH PARTNERS SIGN COMMERCIAL AGREEMENT FOLLOWING SUCCESSFUL UK PILOT

MedX Health Corp. has signed a commercial contract with Health Partners Group Ltd., the United Kingdom's largest occupational health service provider. This agreement follows the successful completion of a pilot project across two of HPG's clients, utilizing MedX's DermSecure skin cancer screening platform.

Following the pilot's success (11 per cent of 300 employees from two of HPG's clients had moles requiring in-clinic dermatological follow-up), MedX's DermSecure skin cancer screening platform will be rolled out to Health Partners' clients across the U.K. and the Republic of Ireland, representing a major milestone in MedX's global commercialization strategy.

"We are thrilled to deepen our relationship with Health Partners through this commercial agreement," said Mike Druhan, president of dermatological services at MedX. "This rollout means potentially thousands of at-risk individuals, particularly outdoor and industrial workers, will gain access to dermatologist-level skin assessments, directly at their workplaces. Health Partners Group is offering MedX services as a fast track to a dermatologist, which is a powerful step forward in the early detection and prevention of skin cancer in the workplace."

With three million client employees served and 650-plus corporate, government and insurance clients, Health Partners Group is poised to offer scalable, remote skin cancer screening as a standard part of its client employee health services.

"The pilot validated the accuracy, speed and accessibility of MedX's technology," said Andrew Noble, chief executive officer of Health Partners Group. "Preventive care is essential to workplace health. Health Partners Group is extending its preventative care and chronic care services to include skin cancer screening. This is a complementary partnership that enables Health Partners to integrate world-class dermatological assessments into our existing services, speeding up diagnosis to under three days from the current NHS wait time of between five and nine months and helping safeguard the health of the U.K.'s work force."

Skin cancer is among the most common forms of cancer in the U.K., with over 220,000 cases diagnosed annually. According to the U.K. Cancer Alliance, outdoor workers face a 60-per-cent-higher risk of developing skin cancer due to prolonged sun exposure. Early detection remains critical, with survival rates dropping sharply between early- and late-stage diagnoses.

The MedX platform allows rapid, non-invasive imaging of skin lesions, which are securely transmitted to dermatologists for assessment within a period of 72 hours or less. The rollout represents a pivotal advancement in accessible, preventative care, especially at a time when health care systems face growing demand and staffing pressures.

About MedX Health Corp.

MedX Health, headquartered in Ontario, Canada, is a leader in non-invasive skin assessment and teledermatology. Its proprietary SIAscopy technology, integrated into the DermSecure platform, enables pain-free, accurate imaging of skin lesions for rapid dermatologist review. These products are cleared by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration, and Conformite Europeenne for use in Canada, the United States, Australia, New Zealand, the United Kingdom, the European Union and Turkey.